140 related articles for article (PubMed ID: 31892925)
1. [Loss to follow-up in patients treated for multidrug-resistant tuberculosis in EcuadorA Perda de seguimento de pacientes tratados para tuberculose multirresistente a medicamentos no Equador].
Tatés-Ortega N; Álvarez J; López L; Mendoza-Ticona A; Alarcón-Arrascue E
Rev Panam Salud Publica; 2019; 43():e91. PubMed ID: 31892925
[TBL] [Abstract][Full Text] [Related]
2. Retreatment after loss to follow-up reduces mortality in patients with multidrug/rifampicin-resistant tuberculosis.
Choi H; Mok J; Ae Kang Y; Jeong D; Kang HY; Kim HJ; Kim HS; Jeon D
ERJ Open Res; 2023 Jul; 9(4):. PubMed ID: 37583964
[TBL] [Abstract][Full Text] [Related]
3. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
Garg K; Saini V; Dhillon R; Agarwal P
Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492
[TBL] [Abstract][Full Text] [Related]
4. Travel distance to rifampicin-resistant tuberculosis treatment and its impact on loss to follow-up: the importance of continued RR-TB treatment decentralization in South Africa.
McNabb KC; Bergman AJ; Patil A; Lowensen K; Mthimkhulu N; Budhathoki C; Perrin N; Farley JE
BMC Public Health; 2024 Feb; 24(1):578. PubMed ID: 38389038
[TBL] [Abstract][Full Text] [Related]
5. Predictors of loss to follow-up among adult tuberculosis patients in Southern Ethiopia: a retrospective follow-up study.
Watumo D; Mengesha MM; Gobena T; Gebremichael MA; Jerene D
BMC Public Health; 2022 May; 22(1):976. PubMed ID: 35568853
[TBL] [Abstract][Full Text] [Related]
6. Incidence and predictors of lost to follow-up among drug-resistant tuberculosis patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: a retrospective follow-up study.
Kassa GM; Teferra AS; Wolde HF; Muluneh AG; Merid MW
BMC Infect Dis; 2019 Sep; 19(1):817. PubMed ID: 31533661
[TBL] [Abstract][Full Text] [Related]
7. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
[TBL] [Abstract][Full Text] [Related]
8. Rifampicin-resistant tuberculosis patients in Myanmar in 2016: how many are lost on the path to treatment?
Htet KKK; Soe KT; Kumar AMV; Saw S; Win Maung HM; Myint Z; Khine TMM; Aung ST
Int J Tuberc Lung Dis; 2018 Apr; 22(4):385-392. PubMed ID: 29562985
[TBL] [Abstract][Full Text] [Related]
9. Hearing thresholds in patients with drug-resistant tuberculosis: baseline audiogram configurations and associations.
Sogebi OA; Fadeyi MO; Adefuye BO; Soyinka FO
J Bras Pneumol; 2017; 43(3):195-201. PubMed ID: 28746530
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan.
Makhmudova M; Maxsumova Z; Rajabzoda A; Makhmadov A; van den Hof S; Mirtskhulava V
Int J Tuberc Lung Dis; 2019 Mar; 23(3):331-336. PubMed ID: 30871664
[TBL] [Abstract][Full Text] [Related]
11. What happened to patients with RMP-resistant/MDR-TB in Zambia reported as lost to follow-up from 2011 to 2014?
Kasapo CC; Chimzizi R; Simwanza SC; Mzyece J; Chizema E; Mariandyshev A; Lee HY; Harries AD; Kapata N
Int J Tuberc Lung Dis; 2017 Aug; 21(8):887-893. PubMed ID: 28786797
[TBL] [Abstract][Full Text] [Related]
12. Determinant factors for loss to follow-up in drug-resistant tuberculosis patients: the importance of psycho-social and economic aspects.
Soedarsono S; Mertaniasih NM; Kusmiati T; Permatasari A; Juliasih NN; Hadi C; Alfian IN
BMC Pulm Med; 2021 Nov; 21(1):360. PubMed ID: 34758794
[TBL] [Abstract][Full Text] [Related]
13. Loss to follow-up among patients diagnosed with spinal tuberculosis at a tertiary hospital in Western Cape Province, South Africa: A retrospective cohort study.
Mann TN; Davis JH; Dyers R
S Afr Med J; 2020 Mar; 110(4):284-290. PubMed ID: 32657739
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
[TBL] [Abstract][Full Text] [Related]
16. Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015.
Matambo R; Takarinda KC; Thekkur P; Sandy C; Mharakurwa S; Makoni T; Ncube R; Charambira K; Zishiri C; Ngwenya M; Nyathi S; Chiteka A; Chikaka E; Mutero-Munyati S
PLoS One; 2020; 15(4):e0230848. PubMed ID: 32353043
[TBL] [Abstract][Full Text] [Related]
17. Low BMI increases all-cause mortality rates in patients with drug-resistant TB.
Adamashvili N; Baliashvili D; Kuchukhidze G; Salindri AD; Kempker RR; Blumberg HM; Lomtadze N; Avaliani Z; Magee MJ
Int J Tuberc Lung Dis; 2022 Apr; 26(4):326-333. PubMed ID: 35351237
[TBL] [Abstract][Full Text] [Related]
18. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
[TBL] [Abstract][Full Text] [Related]
19. Factors contributing to the high prevalence of multidrug-resistance/Rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk krai region of Russia.
Bykov I; Dyachenko O; Ratmanov P; Liu H; Liang L; Wu Q
BMC Infect Dis; 2022 Jul; 22(1):612. PubMed ID: 35831812
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with unfavourable treatment outcomes among people with rifampicin-resistant tuberculosis in Armenia, 2014-2017.
Khachatryan L; Grigoryan R; Dadu A; Kumar AMV; Akopyan K; Dumchev K; Harutyunyan H; Matteelli A
Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
